TGFB1 and neoplasm: To assess the diffusion of CSF1R/CCR2/TGF-β Ab from the vasculature and its ability to reach the tumor spheroids, we perfused a device with fluorescently labeled CSF1R/CCR2/TGF-β Ab and found that the drug could penetrate the spheroid compartment within 2 hours after perfusion (Fig. S14).